InvestSMART

Bioxyne Limited (ASX:BXN)

ALERT: Price-sensitive ASX Announcement for BXN
Current share price for BXN : $0.930 0.858 (1,191.67%)+
Announcement
Release
12 May 2026 8:22AM
Price at Release
$0.072
Full Release
download
Summary
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a two-year, $50 million exclusive supply agreement with German pharmaceutical company ADREXpharma GmbH. The agreement, which includes a $25 million minimum commitment in the first 12 months, focuses on the supply of GMP-certified medicinal cannabis products in Germany. This deal not only enhances Bioxyne's presence in Germany, Europe's largest medicinal cannabis market, but also strengthens its position in the broader European market. The agreement supports Bioxyne's strategy to expand its GMP-certified manufacturing and supply platform across regulated international markets, emphasizing its growth in pharmaceuticals and controlled substances.
Key Points
  • Bioxyne secures $50 million exclusive supply agreement with ADREXpharma.
  • Agreement includes a $25 million minimum commitment in the first 12 months.
  • ADREXpharma granted exclusive rights for the Dr Watson® brand in Germany.
  • Strengthens Bioxyne’s position in Europe's largest medicinal cannabis market.
  • Aligns with Bioxyne’s strategy to scale GMP-certified manufacturing.
  • Bioxyne is expanding into additional medicines and controlled substances.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.